← Leaderboards
David B. Miklos
Dana-Farber Cancer Institute
$5,009,214
Attributed
$5,009,214
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,945,230 · 9
By mechanism
P01$5,678,129 · 5
U54$1,185,739 · 2
K08$647,487 · 1
R21$433,875 · 1
Top collaborators
- Robert S Negrin1 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Haesook Kim$5,471,874
- Joseph H Antin$7,618,391
- John G. Gribben$4,031,248
- David Morse Livingston$29,482,838
- Ellis L Reinherz$59,058,313
Others in their field
Top investigators on “Allogenic”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Mary M Horowitz · Medical College Of Wisconsin$47,632,939
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$40,815,122
- Marcel R M Van Den Brink · Sloan-Kettering Institute For Cancer Res$39,678,762
- Bruce R. Blazar · University Of Minnesota$37,193,531
- Megan Sykes · Columbia University Health Sciences$33,587,479
Research focus
AllogenicB-LymphocytesResponseBloodPreventSkinAntibodiesImmuneHematopoieticHematologic NeoplasmsInsightProteinsChronic Graft Versus Host DiseaseLeukemiaHematopoietic NeoplasmsCell TransplantationImmune ResponseRecurrent DiseaseGraft-Vs-Host DiseaseBone Marrow TransplantationPathogenesisIn VivoAffectRefractory
Grant awards (25)
Bone Marrow Grafting and Cellular Therapy for Leukemia and Lymphoma$2,936,016
P01 · FY2025 · CA
Correlative Science$489,142
P01 · FY2025 · CA · contact PI
Donor Derived CD19/CD22 CAR T Cells as Concurrent Therapy Against Relapse in Adults with B-ALL$465,085
P01 · FY2025 · CA · contact PI
Improving Graft-versus-Leukemia Alloimmunity against CLL$135,777
P01 · FY2017 · CA · contact PI
Improving Graft-versus-Leukemia Alloimmunity against CLL$135,776
P01 · FY2016 · CA · contact PI
Improving Graft-versus-Leukemia Alloimmunity against CLL$135,776
P01 · FY2015 · CA · contact PI
Improving Graft-versus-Leukemia Alloimmunity against CLL$131,702
P01 · FY2014 · CA · contact PI
Biology and Treatment of Cutaneous Sclerosis$294,778
U54 · FY2013 · CA · contact PI
Improving Graft-versus-Leukemia Alloimmunity against CLL$135,776
P01 · FY2013 · CA · contact PI
Biology and Treatment of Cutaneous Sclerosis$209,152
U54 · FY2012 · CA · contact PI
Allogeneic B Cell Responses$250,206
P01 · FY2011 · CA · contact PI
Biology and Treatment of Cutaneous Sclerosis$213,336
U54 · FY2011 · CA · contact PI
Biology and Treatment of Cutaneous Sclerosis$233,256
U54 · FY2010 · AI · contact PI
Allogeneic B Cell Responses$219,396
P01 · FY2010 · CA · contact PI
Biology and Treatment of Cutaneous Sclerosis$235,217
U54 · FY2009 · AI · contact PI
Allogeneic B Cell Responses$215,119
P01 · FY2009 · CA · contact PI
Microarray Analysis of H-Y Antibodies in Human Transplantation$237,000
R21 · FY2008 · HL · contact PI
Allogeneic B Cell Responses$213,245
P01 · FY2008 · CA · contact PI
Allogeneic B Cell Responses$215,113
P01 · FY2007 · CA · contact PI
Microarray Analysis of H-Y Antibodies in Human Transplantation$196,875
R21 · FY2007 · HL · contact PI
Identification of Minor Histocompatibility Antigens$132,705
K08 · FY2006 · HL · contact PI
Identification of Minor Histocompatibility Antigens$132,705
K08 · FY2005 · HL
Identification of Minor Histocompatibility Antigens$127,359
K08 · FY2004 · HL
Identification of Minor Histocompatibility Antigens$127,359
K08 · FY2003 · HL
Identification of Minor Histocompatibility Antigens$127,359
K08 · FY2002 · HL